US Stock MarketDetailed Quotes
IMMU Immunomedics
- 0.000
- 0.0000.00%
Close Sep 27 09:30 ET
0Market Cap0.00P/E (TTM)
0.000High0.000Low0Volume0.000Open0.000Pre Close0.00Turnover0.00%Turnover Ratio0.00P/E (Static)231.16MShares87.93052wk High0.00P/B0Float Cap87.59052wk Low--Dividend TTM204.63MShs Float87.930Historical High--Div YieldTTM0.00%Amplitude0.840Historical Low--Avg Price1Lot Size
Immunomedics Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2020 | (Q1)Mar 31, 2020 | (FY)Dec 31, 2019 | (Q4)Dec 31, 2019 | (Q3)Sep 30, 2019 | (Q2)Jun 30, 2019 | (Q1)Mar 31, 2019 | (FY)Dec 31, 2018 | (Q4)Jun 30, 2018 | (Q3)Mar 31, 2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -146.65%-30.82M | -31.45%-71.87M | -70.24%-222.44M | -147.28%-92.66M | -94.58%-62.61M | -12.5M | -54.68M | -109.90%-130.66M | -166.44%-37.47M | -92.92%-32.17M |
| Net income from continuing operations | 12.45%-66.5M | -6.49%-93.08M | -126.51%-357.32M | 14.87%-99.64M | -165.26%-94.32M | ---75.95M | ---87.4M | -2.92%-157.75M | -119.72%-117.04M | 40.06%-35.56M |
| Operating gains losses | --0 | --87K | 297.83%1M | --0 | ---- | ---- | ---- | -100.74%-507K | 130.77%58.86M | -127.33%-9.84M |
| Depreciation and amortization | -5.70%976K | 19.40%960K | 82.09%3.82M | 122.86%795K | 280.06%1.19M | --1.04M | --804K | 127.41%2.1M | 23.04%356.73K | 79.98%312.59K |
| Other non cash items | 34.04%14.06M | 35.07%13.56M | 106.29%40.24M | -49.97%10.18M | 4,407.82%9.53M | --10.49M | --10.04M | 1,471.96%19.51M | 43,774.42%20.35M | -168.79%-221.27K |
| Change In working capital | -72.96%13.39M | -86.34%2.75M | 1,431.14%78.07M | -521.14%-8.41M | 42.40%16.82M | --49.53M | --20.14M | -67.81%5.1M | -111.64%-1.35M | 135.21%11.81M |
| -Change in receivables | ---- | ---- | -741.30%-295K | ---- | ---- | ---- | ---- | -85.89%46K | -68.79%158.32K | ---- |
| -Change in inventory | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --0 | -100.01%-16 | ---- |
| -Change in prepaid assets | ---- | ---- | -958.18%-16.42M | ---- | ---- | ---- | ---- | -1,500.00%-1.55M | -1,055.85%-4.29M | ---- |
| -Change in payables and accrued expense | ---- | ---- | 1,987.53%29.98M | ---- | ---- | ---- | ---- | -90.92%1.44M | -30.26%7.95M | ---- |
| -Change in other current assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --5.17M | ---- | ---- |
| -Change in other working capital | 13.39%56.16M | -86.34%2.75M | --64.81M | ---21.67M | --16.82M | --49.53M | --20.14M | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -146.65%-30.82M | -31.45%-71.87M | -70.24%-222.44M | -147.28%-92.66M | -94.58%-62.61M | ---12.5M | ---54.68M | -109.90%-130.66M | -166.44%-37.47M | -92.92%-32.17M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 76.59%-851K | 77.08%-473K | -164.58%-6.85M | -101.66%-335K | -103.42%-815K | -3.64M | -2.06M | 113.91%10.61M | 122.85%20.22M | 36.88%23.81M |
| Net PPE purchase and sale | 76.59%-851K | 77.08%-473K | 38.92%-6.85M | 93.36%-335K | 72.28%-815K | ---3.64M | ---2.06M | -510.40%-11.21M | -400.68%-5.05M | -2,878.92%-2.94M |
| Net investment purchase and sale | ---- | ---- | --0 | --0 | ---- | ---- | ---- | 129.31%21.82M | 128.88%25.27M | 52.91%26.75M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 76.59%-851K | 77.08%-473K | -164.58%-6.85M | -101.66%-335K | -103.42%-815K | ---3.64M | ---2.06M | 113.91%10.61M | 122.85%20.22M | 36.88%23.81M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 7,535.94%466.56M | -98.25%32K | 20,664.41%347.18M | 4.90%339.07M | -99.93%175K | 6.11M | 1.83M | -99.01%1.67M | 160.33%323.23M | 1,473.12%254.11M |
| Net issuance payments of debt | ---- | ---- | --0 | --0 | ---- | ---- | ---- | --0 | ---1K | ---- |
| Net common stock issuance | ---- | ---- | --344.63M | 39.00%338.8M | --0 | ---- | ---- | --0 | 51,531,191.54%243.74M | 396.82%73.03M |
| Net preferred stock issuance | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| Proceeds from stock option exercised by employees | 598.58%1.96M | -98.25%32K | 36.96%2.55M | -99.66%272K | -47.31%175K | --281K | --1.83M | -56.55%1.86M | 3,108.83%79.49M | -80.55%332.11K |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 64.84%-192K | 102.31%2.25K | -479.34%-1.47M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 7,535.94%466.56M | -98.25%32K | 20,664.41%347.18M | 4.90%339.07M | -99.93%175K | --6.11M | --1.83M | -99.01%1.67M | 160.33%323.23M | 1,473.12%254.11M |
| Net cash flow | ||||||||||
| Beginning cash position | 22.87%539.71M | 23.85%612.04M | -19.33%494.17M | 19.31%365.97M | 604.10%429.22M | --439.25M | --494.17M | 4,539.37%612.58M | 1,300.77%306.75M | 1,116.45%60.96M |
| Current changes in cash | 4,439.73%434.88M | -31.68%-72.31M | 199.58%117.89M | -19.58%246.07M | -125.74%-63.25M | ---10.02M | ---54.92M | -490.85%-118.39M | 1,317.75%305.99M | 1,356.87%245.74M |
| Effect of exchange rate changes | 380.00%14K | -111.11%-19K | 0.00%-22K | 101.33%2K | -120.88%-10K | ---5K | ---9K | 78.00%-22K | -71.61%-149.82K | 144.54%47.9K |
| End cash Position | 127.06%974.61M | 22.87%539.71M | 23.85%612.04M | -0.09%612.04M | 19.31%365.97M | --429.22M | --439.25M | 1,038.80%494.17M | 1,311.67%612.58M | 1,300.77%306.75M |
| Free cash flow | -96.34%-31.67M | -27.50%-72.35M | -61.61%-229.29M | -118.73%-93M | -80.61%-63.42M | ---16.13M | ---56.74M | -121.38%-141.88M | -182.10%-42.52M | -109.31%-35.11M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data